- About Us
- Research & Pipeline
- Investor Centre
- Media Centre
The Australian phase 1 clinical trial of the drug Cantrixil for recurrent ovarian cancer could shape the next wave of clinical research into drugs targeting cancer stem cells, a peer-reviewed paper published in Expert Opinion on Orphan Drugs this month has found.
Kazia Therapeutics recently released preliminary data from its phase 1 clinical study of Cantrixil, a potential new treatment for recurrent ovarian cancer.
Sydney, 25 June 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to invite shareholders to attend information briefing sessions to discuss the company’s recent activities.
A breakthrough new treatment for ovarian cancer that aims to stop the disease returning by killing off the cancer’s stem cells is undergoing safety trials in Australia.
A prominent Australian oncology researcher says ovarian cancer patients are losing out as badly-needed funds and clinical attention is focused on more prominent – yet not as deadly – women’s diseases.
Kazia was delighted recently to have the members of our Scientific Advisory Board gather in Sydney. We spent time working through details of our clinical trials for GDC-0084, our potential brain cancer therapeutic, and Cantrixil, our drug in development for ovarian cancer. Stuart Roberts, Senior Analyst at NDF Research took the opportunity to conduct wide-ranging interviews with each of the SAB members, which provide rich insights into their work.
Enter your email address to subscribe to our insights and receive notifications of new posts by email.
Required values are marked